Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2004

01-01-2004 | Review Article

Gastrointestinal mucositis: a new biological model

Author: Dorothy M. K. Keefe

Published in: Supportive Care in Cancer | Issue 1/2004

Login to get access

Abstract

The history of research into gastrointestinal mucositis (GIM), and how the future directions are informed by the progress made in the study of oral mucositis (OM) are discussed. It is proposed that OM and GIM should both be considered to be elements of alimentary mucositis (AM), which covers mucosal damage through the entire alimentary tract, with regional differences being due to the specialized needs of each area.
Literature
1.
Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BG, Cummins AG (2002) The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 50:53–58CrossRefPubMed
2.
Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751–2757CrossRefPubMed
3.
Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18:1095–1100CrossRefPubMed
4.
Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic changes in the mouse ileum and cecum. J Natl Cancer Inst 87:1876–1883PubMed
5.
Keefe DMK (1998) The effect of cytotoxic chemotherapy on the mucosa of the small intestine. Department of Medicine, University of Adelaide, Adelaide
6.
Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE (1997) Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci 92:385–389PubMed
7.
Keefe DM, Brealey J, Goland GJ, Cummins AG (2000) Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47:632–637CrossRefPubMed
8.
Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43PubMed
9.
Trier JS (1962) Morphological alterations induced by methotrexate in the mucosa of human proximal intestine I. Serial observations by light microscopy. Gastroenterology 42:295–305PubMed
10.
Trier JS (1962) Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine II. Electron microscopic observations. Gastroenterology 43:407–424PubMed
Metadata
Title
Gastrointestinal mucositis: a new biological model
Author
Dorothy M. K. Keefe
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/2004
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-003-0550-9

Other articles of this Issue 1/2004

Supportive Care in Cancer 1/2004 Go to the issue

Editorial

Electronic processing of papers

Letter to the Editor

Reply to letter from Russo

Original Article

The burden of the ‘RA RA’ positive: survivors’ and hospice patients’ reflections on maintaining a positive attitude to serious illness

Original Article

Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis

Review Article

What is wrong with the 30-year-old practice of scalp cooling for the prevention of chemotherapy-induced hair loss?

Society News

January 2004
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits